China’s NMPA and NHC Tighten Control on Psychotropic Substances with New Regulations
The National Medical Products Administration (NMPA) and the National Health Commission (NHC) of China have...
Jiuzhou Pharmaceutical Expands Global Footprint with $9.5 Million German CRO Subsidiary
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a leading Chinese pharmaceutical company, has announced plans...
Fosun Pharmaceutical’s Humira Biosimilar Gains New Indications with NMPA Approval
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its biosimilar...
Simcere Pharmaceutical’s Quviviq Secures Hong Kong Marketing Approval for Insomnia Treatment
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received marketing approval...
NK CellTech’s NK-Cell Therapy Gets Green Light from China’s NMPA for Solid Tumor Treatment
NK CellTech, a Shanghai-based developer of natural killer (NK) cell therapies, has announced that it...
C.Q. Pharmaceutical and JD.com Join Forces to Revolutionize Pharmaceutical Supply Chain
C.Q. Pharmaceutical Holding Co., Ltd (SHE: 000950), a prominent Chinese pharmaceutical company, has announced a...
AstraZeneca Partners with Nona Biosciences in Multimillion-Dollar Monoclonal Antibody Agreement
HBM Holdings Ltd’s (HKG: 2142) wholly-owned subsidiary, Nona Biosciences, has announced a significant licensing agreement...
Fosun Diagnostics and Jointown Medical Ink Partnership to Boost Medical Supply Chain
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading healthcare conglomerate in...
Laekna Therapeutics’ mCRPC Drug Combo Advances to Phase III with FDA Approval
Laekna Therapeutics Shanghai Co., Ltd, a biopharmaceutical company based in China, has announced that it...
Changchun High & New Technology Industries Gets Green Light for Jinnamab Clinical Trial
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661), a leading biopharmaceutical company based...
Amoy Diagnostics Teams Up with Boehringer Ingelheim for CDx Developmen
Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a prominent player in China’s tumor precision medicine...
FDA Alert: Chinese Syringe Maker Jiangsu Shenli Initiates Voluntary Recall
This week, the US Food and Drug Administration (FDA) provided a status report on its...
Porton Pharma Solutions Invests €50 Million in Slovenian R&D Expansion
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions Ltd has inaugurated a new...
MilliporeSigma Avoids Prosecution in Biochemical Diversion Case: A DoJ First
Merck KGaA (NYSE: MRK)’s US life sciences division, MilliporeSigma, has been at the center of...
AstraZeneca Sets Sights on $80 Billion Revenue Target and 20 New Molecular Entities by 2030
At its recent investor day, AstraZeneca plc (NASDAQ: AZN), a prominent UK pharmaceutical company, articulated...
Jiangsu Hengrui’s Fluzoparib Gains NMPA Approval as Maintenance Therapy for Ovarian Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Sichuan Biokin’s BL-B01D1 Advances to Phase III for HR+/HER2- Breast Cancer
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese biopharmaceutical company, has announced the enrollment...
AI in Pharma: MindRank Ltd Joins Forces with Zhejiang Hisun Pharmaceutical for Drug R&D
MindRank Ltd, a China-based artificial intelligence (AI)-driven drug development company, has entered into a strategic...
Alphamab Oncology’s JSKN016 Begins Phase I Clinical Trial for Solid Tumor Treatment
Alphamab Oncology (HKG: 9966), a biopharmaceutical company, has announced that the first patient has been...
Jacobio Pharma’s Gecirasib Gets Priority Review for NSCLC Treatment by China’s NMPA
Jacobio Pharma (HKG: 1167), a leading biopharmaceutical company based in China, has announced that its...